Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2022-08-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
关于对全资子公司新乡精泉生物技术有限公司追加投资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding an additional investment by the parent company into its wholly owned subsidiary. It details the investment amount, the subsidiary's basic information, and the purpose and impact of the investment. It is a formal disclosure of a capital injection but does not contain financial statements or comprehensive financial analysis. The document is relatively short (1474 characters) and serves as a regulatory announcement about a capital/financing activity. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-08-26 Chinese
第四届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 15th meeting of the 4th Board of Directors of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It details the meeting date, attendance, legality, and the approval of an investment proposal in a subsidiary. There is no financial report or detailed financial data presented, nor is it an announcement of voting results at a shareholder meeting. Instead, it is a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2022-08-26 Chinese
关于公司2022年半年度控股股东及其他关联方资金占用情况、公司对外担保情况的独立意见
Audit Report / Information Classification · 95% confidence The document is a statement from the independent directors of the company regarding their independent opinion on the company's half-year (2022) related party fund occupation and external guarantees. It references regulatory rules and confirms compliance and absence of violations. The document is short (523 characters) and is an independent opinion or certification rather than a full financial report. It does not contain financial statements or detailed financial data. This fits the category of an Audit Report / Information (AR) as it is an independent directors' opinion on specific financial compliance matters, not a full annual or interim report. H1 2022
2022-08-23 Chinese
中天国富证券有限公司关于新乡拓新药业股份有限公司2022年半年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a '2022 Half-Year Continuous Supervision Follow-up Report' by a sponsoring securities company regarding a listed company. It details the sponsor's review and supervision activities, compliance with regulations, and any issues found during the half-year period. The content includes oversight of information disclosure, internal controls, fundraising supervision, governance, and regulatory measures taken against the sponsor. The document is a detailed supervisory report for a half-year period, containing substantive information about the company's compliance and governance status, but it is not a full financial report like an interim or annual report. It is a specialized regulatory supervision report related to the sponsor's duties rather than a financial statement or earnings release. Given the nature and content, it fits best under the category of Regulatory Filings (RNS), as it is a regulatory compliance and supervision report that does not fit other specific categories such as Annual Report, Interim Report, or Audit Report. The document length is 3123 characters, which is relatively short but contains detailed supervisory content, not just an announcement or certification. Therefore, the classification is RNS with high confidence.
2022-08-23 Chinese
关于子公司河南省拓新医药研究院有限公司完成工商注册登记并取得营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of business registration and obtaining a business license for a newly established subsidiary company. It includes details about the subsidiary's registration, legal representative, capital, and business scope. There is no financial data, report, or detailed analysis presented. The document is a formal announcement of a corporate event related to the establishment of a subsidiary, not a financial report or management information. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-08-23 Chinese
关于子公司河南鼎新医药科技有限公司完成工商注册登记并取得营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of business registration and obtaining a business license for a newly established subsidiary company. It includes details about the subsidiary's registration, legal representative, capital, and business scope. There is no financial data, no mention of annual or quarterly reports, no voting results, no management changes, and no regulatory certifications. The document is a formal public announcement about a corporate event (subsidiary establishment and registration). This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-23 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.